Ono Pharmaceutical Co. Ltd. has entered into a research collaboration agreement with InveniAI LLC, to identify novel therapeutic targets by leveraging InveniAI’s artificial intelligence (AI) and machine learning (ML).   Under the terms of the agreement, InveniAI will identify novel therapeutic targets in multiple diseases specified by Ono by leveraging InveniAI’s AlphaMeld and ChatAlphaMeld, its AI drug discovery platforms, and propose drug discovery hypotheses for optimization.  ...